- Home
- EVAX vs RNXT Comparison
EVAX vs RNXT Comparison
Compare EVAX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVAX | RNXT |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 37.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVAX | RNXT |
|---|---|---|
| Price | $3.98 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $12.33 | $7.75 |
| AVG Volume (30 Days) | 68.2K | ★ 350.4K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,650,000.00 | $928,000.00 |
| Revenue This Year | $128.77 | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | $0.70 |
| 52 Week High | $12.15 | $1.50 |
Technical Indicators
Market Signals| Indicator | EVAX | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 42.18 |
| Support Level | $3.88 | $0.97 |
| Resistance Level | $4.85 | $1.04 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 8.13 | 2.86 |
Price Performance
Historical ComparisonAbout EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.